| Symbol | RLAY |
|---|---|
| Name | RELAY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 399 BINNEY STREET,2ND FLOOR, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 370-8837 |
| Fax | — |
| — | |
| Website | https://www.relaytx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001812364 |
| Description | Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. Additional info from NASDAQ: |
📋 SANJIV PATEL (Director) plans to sell 145K shares of RELAY THERAPEUTICS INC (at $18.90 each, total $2.7M) Filed: Jul 07, 2026 | ID: 006935
Read moreRahmer Peter 🟡 adjusted position in 46.9K shares of Relay Therapeutics, Inc. (RLAY) at $19.09 Transaction Date: Jun 30, 2026 | Filing ID: 294528
Read moreCatinazzo Thomas 🟡 adjusted position in 187.2K shares (3 derivative) of Relay Therapeutics, Inc. (RLAY) at $17.01 ($4.8M) Transaction Date: Jun 22, 2026 | Filing ID: 281061
Read moreBergstrom Donald A 🟡 adjusted position in 93.5K shares (1 derivative) of Relay Therapeutics, Inc. (RLAY) at $16.94 ($2.4M) Transaction Date: Jun 22, 2026 | Filing ID: 281059
Read more📋 DONALD BERGSTROM (Officer) plans to sell 111K shares of RELAY THERAPEUTICS, INC. (at $15.88 each, total $1.8M) Filed: Jun 22, 2026 | ID: 006399
Read more📋 THOMAS CATINAZZO (Officer) plans to sell 205K shares of RELAY THERAPEUTICS, INC. (at $15.88 each, total $3.3M) Filed: Jun 22, 2026 | ID: 006398
Read moreMazumdar Claire 🟢 acquired 32.9K shares (1 derivative) of Relay Therapeutics, Inc. (RLAY) at $14.09 Transaction Date: Jun 09, 2026 | Filing ID: 265913
Read moreDable Habib J 🟢 acquired 32.9K shares (1 derivative) of Relay Therapeutics, Inc. (RLAY) at $14.09 Transaction Date: Jun 09, 2026 | Filing ID: 265911
Read moreHILL LINDA A 🟢 acquired 32.9K shares (1 derivative) of Relay Therapeutics, Inc. (RLAY) at $14.09 Transaction Date: Jun 09, 2026 | Filing ID: 265907
Read moreBorisy Alexis 🟢 acquired 32.9K shares (1 derivative) of Relay Therapeutics, Inc. (RLAY) at $14.09 Transaction Date: Jun 09, 2026 | Filing ID: 265906
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07584226 | A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors | Phase1 | Advanced NRAS-Mutant Melanoma | Recruiting | 2026-03-09 | 2029-12-31 | ClinicalTrials.gov |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatm… | Phase3 | PIK3CA Mutation | Recruiting | 2025-08-26 | 2031-12-31 | ClinicalTrials.gov |
| NCT06789913 | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Ch… | Phase2 | PIK3CA-Related Overgrowth Spectrum (PROS) | Recruiting | 2025-06-13 | 2031-10-01 | ClinicalTrials.gov |
| NCT05759949 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumo… | Phase1 | PIK3CA Mutation | Completed | 2023-03-29 | 2025-04-11 | ClinicalTrials.gov |
| NCT05216432 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single… | Phase1 | PIK3CA Mutation | Recruiting | 2021-12-08 | 2027-04-30 | ClinicalTrials.gov |
| NCT04622527 | A Study to Assess Virtual Reality by Healthcare Providers: A Pilot Study | Na | Anxiety | Completed | 2021-01-01 | 2022-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-8161 | Other | Phase PHASE1 | Advanced NRAS-Mutant Melanoma | RECRUITING | NCT07584226 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-8161 | Other | Phase PHASE1 | Advanced NRAS-Mutant Melanoma | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Random assigned paradigm viewing order | Other | Approved | Anxiety | COMPLETED | NCT04622527 |
| Abemaciclib | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Ribociclib | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Palbociclib | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Fulvestrant | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| RLY-5836 | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| PF-07220060 300 mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| PF-07220060 100mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Ribociclib 600mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Ribociclib 400mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Palbociclib 125mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Fulvestrant | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| RLY-2608 | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Capivasertib | DRUG | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Placebo | DRUG | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Abemaciclib | DRUG | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Ribociclib | DRUG | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Palbociclib | DRUG | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| RLY-5836 | DRUG | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| PF-07220060 300 mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| PF-07220060 100mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Ribociclib 600mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Ribociclib 400mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Palbociclib 125mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Fulvestrant | DRUG | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | DRUG | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Random assigned paradigm viewing order | OTHER | Approved | Anxiety | COMPLETED | NCT04622527 |